Boost for life sciences as next phase of the Cambridge Biomedical Campus secures planning approval
Cambridge UK, 14 September 2016 – Over 3,500 new jobs will be created and 75,000 sq m of research and development and clinical space will be delivered at the Cambridge Biomedical Campus after proposals from joint developers Liberty Property Trust and Countryside were approved by Cambridge City Council.
The Campus is already a world-renowned centre of clinical and healthcare excellence and has been a growing life sciences hub since the early 1960s. The approved plans for the next phase of the campus will bring forward development of an additional 23 acres of land, carefully masterplanned with a ‘landscape first’ approach. Extensive consultation and engagement helped shape proposals for the expansion which will incorporate state-of-the-art research and development facilities alongside new clinical space for Cambridge University Hospitals, further enhancing this thriving and collaborative community.
The landscape led approach maximises the quality of the open spaces within the development, focusing these on generous courtyards across the site which will be accessible to all. The wider masterplan has been designed to promote and enhance connectivity and communication across the campus, fundamental to its collaborative ethos.
The Cambridge Biomedical Campus is strategically situated two miles south of the city centre and combines world-class biomedical research, patient care and education on a single site. Occupiers on the campus include Cambridge University Hospitals (Addenbrooke’s and The Rosie), the University of Cambridge School of Clinical Medicine, multiple Medical Research Council labs and units as well as the Laboratory of Molecular Biology, and, GlaxoSmithKline. Construction is also underway on a new global research and development centre and corporate headquarters for AstraZeneca and the new Papworth Hospital, a state-of-the-art facility for patients requiring heart and lung treatment.
Andrew Blevins, managing director of Liberty Property Trust, said: “The economic success of the City has taken a giant step forward with the emergence of the Cambridge Biomedical Campus, which is already a truly international centre of healthcare excellence. There remains a strong demand from research institutes and companies to join this life sciences cluster and this decision marks a significant stage in the evolution of the Campus.”
Bidwells, Savills and Creative Partnerships are acting for the developers.
About Cambridge Biomedical Campus
The Cambridge Biomedical Campus combines world-class biomedical research, patient care and education on a single site. Now undergoing a major expansion that includes the co-location of companies alongside the existing 12,000-strong community of healthcare professionals and research scientists, the Campus is on track to becoming one of the leading biomedical centres in the world by 2020. In 2014, the Campus won the prestigious Property Week Place Making Award.
About Liberty Property Trust
Liberty Property Trust UK Ltd is a wholly-owned subsidiary of US-based Liberty Property Trust, a Real Estate Investment Trust, listed on the New York Stock Exchange. Liberty Property Trust (NYSE:LPT), headquartered in Malvern, Pennsylvania, is a leader in commercial real estate, serving customers in the United States and the United Kingdom, through the development, acquisition, ownership and management of superior office and industrial properties. Liberty Property Trust owns and manages more than 750 properties totaling 105 million sq ft, accommodating 1,900 occupiers and has a market capitalisation of $8.8 billion. Visit for more information http://www.libertyproperty.com/
Countryside is a leading UK developer specialising in place making and urban regeneration with experience in delivering commercial development across the full range of market sectors which complement its highly successful residential and mixed use schemes. Countryside’s main emphasis
is on developing commercial space allied to its new communities or regeneration opportunities, such as the adjoining Great Kneighton development. Founded in 1958, Countryside is listed on the London Stock Exchange and operates across London, the South East and the North West of England. For the year ended 30 September 2015, Countryside had revenues of £615.8m.